TB-500 Research Guide 2026: Thymosin Beta-4 Repair
“TB-500” is a supplier/trade name that can refer to full-length thymosin beta-4 (Tβ4, 43 residues) or to a short LKKTETQ-related fragment. Check the supplied sequence and expected mass before applying a paper’s findings. Confirm the linked catalogue material’s sequence and terminal chemistry against the received lot report.
Full Tβ4 binds actin and has been studied in migration and injury models. A seven-residue fragment was tested in an aged-mouse wound model, but it is not interchangeable with the parent peptide across cardiac, corneal or biochemical endpoints. This guide separates those evidence streams.
What is TB-500?
Full-length Tβ4 is a 43-residue peptide of approximately 4.96 kDa, whereas LKKTETQ is a much smaller fragment. The actin-contacting region includes the central motif, but structural work shows contacts extending beyond that motif. A short fragment cannot be assumed to reproduce the full peptide’s actin-sequestering behavior.
A lot report should identify the sequence, modifications and mass assignment; the name “TB-500” alone is insufficient. HPLC area purity is a separate attribute from identity and measured content.
Mechanism of Action
For full Tβ4, structural and experimental work links actin interactions with model-specific migration and repair endpoints. Those findings must remain assigned to the molecule actually tested.
Actin Binding Requires More Than a Motif Label
Structural studies of Tβ4–actin complexes identify distributed peptide contacts. The LKKTET region is important, but it is not by itself a complete demonstration that a seven-residue commercial fragment sequesters actin like full-length Tβ4.
Migration and Wound Models
Philp et al. (2003) studied full Tβ4 and an LKKTETQ fragment in aged mice; both had wound-repair effects in that model. The diabetic-mouse findings were more specific, and keratinocyte migration was not increased there. These experiments do not establish that all Tβ4 migration outcomes occur with the fragment.
Cardiac Injury and ILK/Akt
Bock-Marquette et al. (2004) investigated full Tβ4, including embryonic/postnatal cardiac cells and a mouse coronary-ligation model. The paper reported migration/survival and integrin-linked kinase/Akt-related effects. It is not a seven-residue TB-500 clinical healing study.
Model-Specific Pathway Interpretation
A pathway observed in one wound or cell model should be verified in the intended experiment. Actin remodeling, angiogenesis, inflammatory markers and functional tissue repair are distinct endpoints; none should be treated as a universal consequence of the trade name.
Pharmacokinetics and Half-Life
The cited repair papers do not establish a general two-to-three-hour subcutaneous/IM half-life for a TB-500 fragment. PK must identify the sequence, formulation, species, route and analyte measured. Full Tβ4 clinical development cannot automatically supply the fragment’s human PK.
An assay effect lasting after exposure is not the circulating half-life. Report those measures separately and do not construct a loading schedule from an unsupported PK estimate.
Primary Study Materials and Models
| Primary source | Tested material/model | Endpoint |
|---|---|---|
| Philp et al., 2003 | Full Tβ4 and LKKTETQ fragment; aged-mouse wound experiments | Dermal repair endpoints; findings must be read by model and material |
| Bock-Marquette et al., 2004 | Full Tβ4; cultured cardiac cells and mouse coronary ligation | Migration, survival and ILK/Akt-related responses |
| Structural Tβ4–actin work | Defined Tβ4-derived constructs and actin | Distributed structural contacts, not a universal fragment-equivalence claim |
For replication, take concentrations and routes from the exact experimental methods.
TB-500 vs BPC-157
BPC-157’s rat tendon-cell findings and Tβ4’s actin/wound-model findings motivate different experimental questions. That difference is a hypothesis for comparison or combination, not evidence that a TB-500/BPC-157 stack is the most studied or clinically superior repair protocol.
A useful comparison has matched controls for each single material, the combination and the vehicle, with the actual Tβ4/fragment sequence recorded. See the combination-evidence review.
Safety, Limitations, and Research Gaps
Safety evidence for full Tβ4 and for a short fragment must be evaluated separately. FDA’s current safety-risk page states that it has not identified human-exposure data for the LKKTETQ fragment and identifies peptide-impurity/immunogenicity concerns. Findings from regulated full-length formulations do not approve an arbitrary research vial.
The 2026 WADA list names thymosin-β4 and its derivatives, including TB-500, in S2, prohibited at all times. For study authorization and handling, apply the requirements for the exact material and jurisdiction.
Conclusion
The first question in TB-500 research is molecular identity. Full Tβ4 has actin-binding and model-specific repair findings; a short fragment has a narrower experimental record. Keep each claim attached to the tested sequence and model, and use a lot-specific report before importing a paper’s conclusions into a new study.
Source this peptide for your research
Order TB-500Research source
Source TB-500 for your research
Compare available sizes and check the matching batch certificate before ordering.
View productFrequently Asked Questions
Is TB-500 legal to purchase and study?
Requirements depend on the exact material and jurisdiction. The FDA discusses safety gaps specifically for the LKKTETQ fragment; that should not be silently treated as a finding for every full-length formulation. WADA 2026 prohibits thymosin-β4 and derivatives including TB-500 under S2.
What is the difference between TB-500 and Thymosin Beta-4?
“TB-500” is used for more than one supplied molecule. Full thymosin beta-4 has 43 residues and approximately 4.96 kDa mass; an LKKTETQ-related fragment is much smaller. Check the sequence and lot report. Evidence for the parent cannot automatically be assigned to the fragment.
Is TB-500 orally active?
The cited wound and structural studies do not establish reliable human oral bioavailability for a TB-500-labelled material. Specify the molecule and route in the original experiment before interpreting exposure.
How long do TB-500 effects last after a single dose?
There is no general duration established for all materials sold as TB-500. Circulating parent-peptide half-life, a delayed assay response and a tissue-repair endpoint are different measurements. The sources here do not establish a universal fragment half-life.
What purity standard should research-grade TB-500 meet?
Review the lot-specific report for the exact sequence, modifications, HPLC method/trace and interpreted MS result. A compatible intact mass supports composition but is not complete sequence confirmation. If stock concentration matters, obtain a quantitative target-content basis; HPLC area purity is separate from net content. Select acceptance criteria for the model rather than assuming one percentage measures every quality attribute.
Is TB-500 commonly studied with BPC-157?
Combination use is discussed commercially, but discussion is not controlled combination evidence. The sources cited here do not establish a validated BPC-157/Tβ4 or fragment stack. Test each material and the combination with matched controls if that is the scientific question.
Scientific References
- Philp et al. 2003. Tβ4 and fragment in aged/diabetic wound models. PMID: 12581423 - Primary source[PubMed Reference]
- Bock-Marquette et al. 2004. Full Tβ4 cardiac model. PMID: 15565145 - Primary source[PubMed Reference]
- Structural basis of Tβ4–actin interactions - Primary source
- FDA: LKKTETQ fragment safety-data limits - Primary source
- WADA 2026 Prohibited List, S2 - Primary source
Related Research Peptides
TB-500
BPC-157
